Raptor Pharmaceutical to Present at Upcoming Investor Conference

        Print
| Source: Raptor Pharmaceutical Corp.

NOVATO, Calif., June 12, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Julie Anne Smith, executive vice president, strategy and chief operating officer of Raptor, will present an overview of the company at the Wells Fargo Health Care Conference in Boston. Raptor's presentation will take place on Wednesday, June 19, 2013 beginning at 3:00 p.m. EDT/12:00 p.m. PDT.

A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. is a biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company's first product, PROCYSBI™ (cysteamine bitartrate) delayed-release capsules, has been approved by the FDA and is currently being reviewed by the European Medicines Agency as a potential new treatment for nephropathic cystinosis, a rare metabolic lysosomal storage disease. Raptor's pipeline also includes RP103 in a Phase 2/3 trial for Huntington's disease and a Phase 2 trial in nonalcoholic fatty liver disease in children. For additional information, please visit www.raptorpharma.com.

Georgia Erbez
Chief Financial Officer
Raptor Pharmaceutical Corp.
(415) 382-8111 x204


INVESTOR CONTACTS:
Westwicke Partners, LLC
Stefan Loren, Ph.D.
Managing Director
(443) 213-0507

Robert H. Uhl
Managing Director
(858) 356-5932


MEDIA CONTACT:
Carolyn Hawley
Canale Communications
(619) 849-5375